These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

83 related items for PubMed ID: 6475078

  • 1. [Adjuvant endocrine forms of therapy in breast cancer].
    Jakesz R, Hausmaninger H.
    Wien Klin Wochenschr; 1984 Jun 22; 96(13):492-9. PubMed ID: 6475078
    [Abstract] [Full Text] [Related]

  • 2. Re-evaluating adjuvant breast cancer trials: assessing hormone receptor status by immunohistochemical versus extraction assays.
    Regan MM, Viale G, Mastropasqua MG, Maiorano E, Golouh R, Carbone A, Brown B, Suurküla M, Langman G, Mazzucchelli L, Braye S, Grigolato P, Gelber RD, Castiglione-Gertsch M, Price KN, Coates AS, Goldhirsch A, Gusterson B, International Breast Cancer Study Group.
    J Natl Cancer Inst; 2006 Nov 01; 98(21):1571-81. PubMed ID: 17077359
    [Abstract] [Full Text] [Related]

  • 3. Chemoendocrine compared with endocrine adjuvant therapies for node-negative breast cancer: predictive value of centrally reviewed expression of estrogen and progesterone receptors--International Breast Cancer Study Group.
    Viale G, Regan MM, Maiorano E, Mastropasqua MG, Golouh R, Perin T, Brown RW, Kovács A, Pillay K, Ohlschlegel C, Braye S, Grigolato P, Rusca T, Gelber RD, Castiglione-Gertsch M, Price KN, Goldhirsch A, Gusterson BA, Coates AS.
    J Clin Oncol; 2008 Mar 20; 26(9):1404-10. PubMed ID: 18349391
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Progesterone receptor status provides predictive value for adjuvant endocrine therapy in older estrogen receptor-positive breast cancer patients.
    Yu KD, Liu GY, Di GH, Wu J, Lu JS, Shen KW, Shen ZZ, Shao ZM.
    Breast; 2007 Jun 20; 16(3):307-15. PubMed ID: 17293115
    [Abstract] [Full Text] [Related]

  • 6. Biologic and clinical characteristics of breast cancer with single hormone receptor positive phenotype.
    Rakha EA, El-Sayed ME, Green AR, Paish EC, Powe DG, Gee J, Nicholson RI, Lee AH, Robertson JF, Ellis IO.
    J Clin Oncol; 2007 Oct 20; 25(30):4772-8. PubMed ID: 17876012
    [Abstract] [Full Text] [Related]

  • 7. Prognostic and predictive value of centrally reviewed expression of estrogen and progesterone receptors in a randomized trial comparing letrozole and tamoxifen adjuvant therapy for postmenopausal early breast cancer: BIG 1-98.
    Viale G, Regan MM, Maiorano E, Mastropasqua MG, Dell'Orto P, Rasmussen BB, Raffoul J, Neven P, Orosz Z, Braye S, Ohlschlegel C, Thürlimann B, Gelber RD, Castiglione-Gertsch M, Price KN, Goldhirsch A, Gusterson BA, Coates AS.
    J Clin Oncol; 2007 Sep 01; 25(25):3846-52. PubMed ID: 17679725
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Content of epidermal growth factor receptor in metastatic breast cancer: its role in endocrine sensitivity prediction.
    Nesković-Konstantinović ZB, Nikolić-Vukosavljević DB, Branković-Magić MV, Mitrovic LB, Spuzić I.
    Neoplasma; 2000 Sep 01; 47(2):107-13. PubMed ID: 10985476
    [Abstract] [Full Text] [Related]

  • 12. Gene expression of estrogen receptor, progesterone receptor and microtubule-associated protein Tau in high-risk early breast cancer: a quest for molecular predictors of treatment benefit in the context of a Hellenic Cooperative Oncology Group trial.
    Pentheroudakis G, Kalogeras KT, Wirtz RM, Grimani I, Zografos G, Gogas H, Stropp U, Pectasides D, Skarlos D, Hennig G, Samantas E, Bafaloukos D, Papakostas P, Kalofonos HP, Pavlidis N, Fountzilas G.
    Breast Cancer Res Treat; 2009 Jul 01; 116(1):131-43. PubMed ID: 18668363
    [Abstract] [Full Text] [Related]

  • 13. Retrospective analysis of time to recurrence in the ATAC trial according to hormone receptor status: an hypothesis-generating study.
    Dowsett M, Cuzick J, Wale C, Howell T, Houghton J, Baum M.
    J Clin Oncol; 2005 Oct 20; 23(30):7512-7. PubMed ID: 16234518
    [Abstract] [Full Text] [Related]

  • 14. Two years of adjuvant tamoxifen in premenopausal patients with breast cancer: a randomised, controlled trial with long-term follow-up.
    Rydén L, Jönsson PE, Chebil G, Dufmats M, Fernö M, Jirström K, Källström AC, Landberg G, Stål O, Thorstenson S, Nordenskjöld B, South Swedish Breast Cancer Group, South-East Swedish Breast Cancer Group.
    Eur J Cancer; 2005 Jan 20; 41(2):256-64. PubMed ID: 15661551
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. HER2 status in hormone receptor positive premenopausal primary breast cancer adds prognostic, but not tamoxifen treatment predictive, information.
    Rydén L, Landberg G, Stål O, Nordenskjöld B, Fernö M, Bendahl PO.
    Breast Cancer Res Treat; 2008 May 20; 109(2):351-7. PubMed ID: 17636399
    [Abstract] [Full Text] [Related]

  • 20. High progesterone receptor expression correlates to the effect of adjuvant tamoxifen in premenopausal breast cancer patients.
    Stendahl M, Rydén L, Nordenskjöld B, Jönsson PE, Landberg G, Jirström K.
    Clin Cancer Res; 2006 Aug 01; 12(15):4614-8. PubMed ID: 16899609
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.